Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Lymphoid 2Genitourinary 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diagnostic Tests, Routine × Genitourinary × Clear all
NCT07526545 2026-04-13

UPRISE

University of Michigan Rogel Cancer Center

Phase NA Not yet recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms

NCT05443412 2025-05-20

Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection

Chinese University of Hong Kong

Recruiting
510 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡